2018
DOI: 10.1021/acs.chemrev.8b00138
|View full text |Cite
|
Sign up to set email alerts
|

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

Abstract: Neurodegenerative diseases pose a substantial socioeconomic burden on society. Unfortunately, the aging world population and lack of effective cures foreshadow a negative outlook. Although a large amount of research has been dedicated to elucidating the pathologies of neurodegenerative diseases, their principal causes remain elusive. Metal ion dyshomeostasis, proteopathy, oxidative stress, and neurotransmitter deficiencies are pathological features shared across multiple neurodegenerative disorders. In additio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
455
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 448 publications
(494 citation statements)
references
References 1,203 publications
(2,873 reference statements)
2
455
0
1
Order By: Relevance
“…Flavonoids are group of polyphenolic phytonutrients, found in almost all fruits, flowers, seeds, and vegetables. They are more common in higher plants being abundant in families like Polygonaceae, Rutaceae, Leguminosae, Umbelliferae, and Compositae (Ansari & Khodagholi, 2013;Savelieff et al, 2018). Due to their polyphenolic nature, they have the ability to scavenge free radicals, hydrogen peroxide, and superoxide radical and therefore are neuroprotective (Bui & Nguyen, 2017;Silva et al, 2014).…”
Section: Flavonoidsmentioning
confidence: 99%
See 1 more Smart Citation
“…Flavonoids are group of polyphenolic phytonutrients, found in almost all fruits, flowers, seeds, and vegetables. They are more common in higher plants being abundant in families like Polygonaceae, Rutaceae, Leguminosae, Umbelliferae, and Compositae (Ansari & Khodagholi, 2013;Savelieff et al, 2018). Due to their polyphenolic nature, they have the ability to scavenge free radicals, hydrogen peroxide, and superoxide radical and therefore are neuroprotective (Bui & Nguyen, 2017;Silva et al, 2014).…”
Section: Flavonoidsmentioning
confidence: 99%
“…In the case of neoflavonoids, B ring is attached in position 4 of C ring that is, 4-phenylcoumarine structure. While in case of the following subgroups: flavones, flavonols, flavanones, flavan-3-ol or flavanols or catechins and chalcones, the B ring is attached to position 2 of C ring; only differs in the structural features of the C ring (Figure 6)(Panche, Diwan, & Chandra, 2016;Savelieff et al, 2018).…”
mentioning
confidence: 99%
“…Anti-aggregation assay: aSyn solutions (0.5 mg mL À1 )w ere buffered at pH 6.6 and 7.4 (MOPS, 20 mm). Iron-and copper-mediated aggregation of aSyn was studied using suitable FeCl 3 and Cu(ClO 4 ) 2 solutions in order to have af inal concentration of 265 mm in cuvette as reported elsewhere. [37] CyD derivatives were added in an equimolar amount to the copper ions.…”
Section: Synthesismentioning
confidence: 99%
“…[1,2] Moreover,t he use of chelating agents has also been proposed for neurodegeneratived isorders relatedt oo xidative stress, and the disruption of metal and cholesterol homeostasis. [3,4] Deferasirox (3,E xjade, ICL670) is an orally available, once-daily, clinicali ron chelator commonly used to treat hemosiderosis resulting from multiple blood transfusions, non-transfusion-dependent thalassemia (NTDT), sickle-cell anemia, or myelodysplastic syndromes (MDS). [5] The development of chelating agents for iron, which currently includes desferal,d eferiprone, and deferasirox, is challenging given the various side-effect drawbacks associated with these agents.…”
Section: Introductionmentioning
confidence: 99%
“…On the one hand, the combination of the AChE inhibitor donepezil with the glutamate NMDA antagonist memantine has proven to lead to additive or synergistic effects in mouse models and AD patients [15][16][17], and a fixed-dose combination of both drugs (Namzaric®) is now being used as the standard of care to treat dementia associated with moderate to severe stages of the disease [18,19]. On the other hand, AD is one of the therapeutic areas where the development of multitarget drugs has been more intensively pursued in the past decade [20][21][22]. Most of these compounds are hybrids that combine distinct pharmacophoric moieties to confer multiple activities [for recent examples see [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37].…”
Section: Introductionmentioning
confidence: 99%